Urological Problems in Patients with Menkes Disease

Mi Young Kim; Ji Hyun Kim; Myung Hyun Cho; Young Hun Choi; Seong Heon Kim; Young Jae Im; Kwanjin Park; Hee Gyung Kang; Jong-Hee Chae; Hae Il Cheong

doi:10.3346/jkms.2019.34.e4

Journal List > J Korean Med Sci > v.34(1) > 1110757

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim, Kim, Cho, Choi, Kim, Im, Park, Kang, Chae, and Cheong: Urological Problems in Patients with Menkes Disease

Original Article

Pediatrics

Journal of Korean Medical Science 2018; 34(1): e4.

Published online: 26 December 2018

DOI: https://doi.org/10.3346/jkms.2019.34.e4

Urological Problems in Patients with Menkes Disease

Mi Young Kim¹

, Ji Hyun Kim¹

, Myung Hyun Cho¹

, Young Hun Choi²

, Seong Heon Kim³

, Young Jae Im⁴

, Kwanjin Park⁴

, Hee Gyung Kang¹

, Jong-Hee Chae⁵

, Hae Il Cheong^1,⁶

¹Department of Pediatrics, Seoul National University Children's Hospital, Seoul, Korea.

²Department of Radiology, Seoul National University Children's Hospital, Seoul, Korea.

³Department of Pediatrics, Pusan National University Children's Hospital, Yangsan, Korea.

⁴Division of Pediatric Urology, Seoul National University Children's Hospital, Seoul, Korea.

⁵Department of Pediatrics, Pediatric Clinical Neuroscience Center, Seoul National University Children's Hospital, Seoul, Korea.

⁶Kidney Research Institute, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea.

Address for Correspondence: Hae Il Cheong, MD, PhD. Department of Pediatrics, Seoul National University Children's Hospital, Kidney Research Institute, Medical Research Center, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea. cheonghi@snu.ac.kr

Received 4 August 2018 Accepted 11 August 2018

The Korean Academy of Medical Sciences

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Menkes disease (MD) is a rare X-linked hereditary multisystemic disorder that is caused by dysfunction of copper metabolism. Patients with MD typically present with progressive neurodegeneration, some connective tissue abnormalities, and characteristic “kinky” hair. In addition, various types of urological complications are frequent in MD because of underlying connective tissue abnormalities. In this study, we studied the clinical features and outcomes of MD, focusing on urological complications.

Methods

A total of 14 unrelated Korean pediatric patients (13 boys and 1 girl) with MD were recruited, and their phenotypes and genotypes were analyzed by retrospective review of their medical records.

Results

All the patients had early-onset neurological deficit, including developmental delay, seizures, and hypotonia. The girl patient showed normal serum copper and ceruloplasmin levels as well as milder symptoms. Mutational analysis of the ATP7A gene revealed 11 different mutations in 12 patients. Bladder diverticula was the most frequent urological complication: 8 (57.1%) in the 14 patients or 8 (72.7%) in the 11 patients who underwent urological evaluation. Urological imaging studies were performed essentially for the evaluation of accompanying urinary tract infections. Four patients had stage II chronic kidney disease at the last follow-up.

Conclusion

Urologic problems occurred frequently in MD, with bladder diverticula being the most common. Therefore, urological imaging studies and appropriate management of urological complications, which may prevent or reduce the development of urinary tract infections and renal parenchymal damage, are required in all patients with MD.

Graphical Abstract

Keywords: ATP7A Gene, Chronic Kidney Disease, Menkes Disease, Urinary Bladder Diverticula, Urological Complication

INTRODUCTION

Menkes disease (MD) is a very rare hereditary multisystemic disorder of copper metabolism with an X-linked recessive inheritance.1 2 3 MD is alternatively described as “kinky hair disease,” because of the characteristic sparse and steely gray or bright-colored hair of the patients. MD is caused by a defect in the ATP7A gene, which encodes a trans-membrane copper-transporting P-type ATPase, ATP7A.4 5 6 Defective copper transport in MD leads to malfunction of one or more copper-requiring enzymes (cuproenzymes), including lysyl oxidase, cytochrome c oxidase, tyrosinase, extracellular superoxide dismutase, and peptidylglycine α-amidating monooxgenase.7 8 9 10 11 The diverse clinical features of MD are attributable to the malfunction of one or more cuproenzymes.12

Patients with MD typically present with progressive neurodegeneration, some connective tissue abnormalities, and characteristic “kinky” hair. Various kinds of urological complications are also frequently observed in MD, including bladder diverticula, bladder outflow obstruction, vesicoureteral reflux, renal rupture, and cryptorchidism.13 These conditions predispose patients with MD to recurrent urinary tract infections and renal parenchyma damage. However, systematic studies on urological complications have not been reported extensively.

In this study, we analyzed the clinical features, image findings, and outcomes of urological complications in 14 Korean pediatric patients with MD.

METHODS

A total of 14 unrelated Korean pediatric patients diagnosed with MD at Seoul National University Children's Hospital, Seoul, Korea or Pusan National University Children's Hospital, Yangsan, Korea between 2005 and 2017 were included in this study. The phenotypes of the patients, with focus on accompanying urologic problems, were analyzed by retrospective review of the medical records. Mutational analysis of the ATP7A gene was carried out by direct sequencing and/or multiplex ligation-dependent probe amplification.14 Genomic DNA was isolated from peripheral blood leukocytes. The cases of seven patients (patients 1, 3–6, 9, and 12) have already been reported.14

Ethics statement

This study was approved by the Institutional Review Board (IRB) of the Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea (IRB No. 1408-010-599). The parents of the patients provided informed consent to participate in this study.

RESULTS

Initial presentation of the patients

Among the 14 patients, 13 were boys and one (patient 14) was a girl. The median gestational period and birth weight were 38 weeks (ranges, 36⁺¹–41 weeks) and 3.06 kg (ranges, 2.50–3.80 kg), respectively. None of the patients had any serious perinatal problems. All the patients presented with neurologic deficits, including developmental delay (n = 7), seizures (n = 6), and hypotonia (n = 3). The onset age was within 4 months after birth in 12 patients, while the remaining two patients, one without a pathogenic mutation and the other being the girl patient, presented with developmental delay at the age of 10 months and 13 months, respectively. The initial serum copper level was available for 11 patients, with a median value of 17.5 μg/dL (ranges, 7–66 μg/dL; normal, 65–140 μg/dL). The initial serum ceruloplasmin level (n = 10) was ≤ 10 mg/dL (normal, 15–40 mg/dL) in all patients except the girl patient, who had normal initial serum copper and ceruloplasmin levels (Table 1).

Table 1

Phenotypes and genotypes of the patients

Pt	GA, wk	BWt, kg	Initial symptoms	Onset, months	ATP7A mutations	Serum copper, µg/dL	Serum ceruloplasm, mg/dL
1	37⁺⁵	2.50	Seizure	3	Exon 6–7 deletion^a	12.9	< 7
2	38⁺⁶	3.10	DD	4	c.1303delA, p.A434Qfs*2^a	16.2	< 7
3	39⁺⁴	3.80	Seizure	4	c.2179G>A, p.G727R	36.1	< 7
4	38	2.80	DD	3	c.2446C>T, p.Q816*	24.5	10.0
5	37	2.70	Seizure, DD	3	c.2179G>A, p.G727R	15.0	< 8.6
6	40	3.43	DD	10	Not detected	17.5	< 8
7	37	3.07	Seizure	3	Exon 19–21 deletion^a	7.0	6.0
8	36⁺¹	2.50	Hypotonia	At birth	c.2627-2A>G^a	11.18	6.7
9	38	3.29	DD, hypotonia	3	c. 601C>T, p.R201*	NA	NA
10	38	2.50	Seizure	3	Exon 3–23 deletion	20.5	< 7
11	36⁺³	2.54	Hypotonia	4	Exon 16 deletion^a	NA	NA
12	39⁺⁴	3.50	DD	3	Not done	32.5	NA
13	37	3.04	Seizure	3	c.3335delA, p.Q1112Rfs*26^a	NA	NA
14^b	41	3.32	DD	13	c.4048G>A, p.E1350K^a	66.0	19.3

Pt = patient, GA = gestational age, BWt = birth weight, DD = developmental delay, NA = not available.

^aNovel mutations; ^bGirl patient.

Mutational analyses of the ATP7A gene

Mutational study of the ATP7A gene was performed for 13 patients, and it revealed 11 different pathogenic mutations in 12 patients, including 4 large deletions, 2 missense mutations, 2 nonsense mutations, 2 frame-shifting short deletions, and 1 abnormal splicing mutation. Seven mutations were novel. No mutation was detected in patient 6, and the mutational study was not done for patient 12. Family history of MD was negative in all patients except one (patient 7), who had an affected younger brother. Genetic testing was performed on the family members of the patients, and the mother of patients 7 was found to be heterozygous carrier of the mutation found in her son (Table 1).

Urological problems

Imaging studies of the kidney and urinary tract were performed for 11 patients (patients 1–11), and bladder diverticula was the most common finding detected in eight patients (patients 1–8) (Fig. 1A). Neurogenic bladder dysfunction was noted in two patients (patients 6 and 7). In patient 6, ultrasonography revealed diffuse wall thickening of the urinary bladder (UB) with multiple bladder diverticula (Fig. 1B), and a urodynamic study revealed neurogenic overactivity of the detrusor muscle and synergic sphincter muscle without vesicoureteral reflux. Imaging studies of patient 7 revealed bilateral vesicoureteral reflux on voiding cystourethrography and diffuse wall thickening of the UB with bladder diverticulum on ultrasonography. However, an urodynamic study was not performed in patient 7 due to lack of parental consent. Bilateral hydroureter was detected in patient 3, and small renal cortical scar on the left upper pole of the kidney was detected on technetium-99m dimercaptosuccinic acid renal scan in patient 2. The imaging studies (n = 8) were performed chiefly as part of a diagnostic work-up for concomitant urinary tract infections. Urinary tract infections developed recurrently in three patients. Two patients received urological treatment: patient 6, who had severe neurogenic bladder dysfunction, underwent bladder diverticulectomy at the age of 5 years, and patient 7, who had bilateral vesicoureteral reflux and 19 episodes of urinary tract infection, underwent ureteroneocystostomy at the age of 1 year.

Fig. 1

Image findings of two common urological complications of Menkes disease, bladdr diverticuli and neurogenic bladder dysfunction. (A) Voiding cystourethrogram (patient 5) demonstrates multiple diverticuli (asterisks) arising from the UB. (B) Pelvic ultrasonogram (patient 2) with a high-frequency linear transducer reveals diffuse wall thickening (lines with a double arrow) of the UB and multiple diverticuli (asterisks).

UB = urinary bladder.

Other organ manifestations that were detected were pectus excavatum (n = 6), inguinal hernia (n = 5), intracranial hemorrhage/cephalhematoma (n = 4), hip dislocation (n = 2), and diaphragmatic hernia (n = 1) (Table 2).

Table 2

Associated abnormalities in the urinary tract and other organs

Pt	No. of UTI	No. of bladder diverticula (detection age in months)	Other urologic abnormalities	eGFR^c	Other organ abnormalities	Current status (age in months)
1	2	> 3 (6)	None	118	Pectus excavatum	Survived (75)
					Inguinal hernia
					Failure to thrive
2	1	> 3 (4)	Renal cortical scar on left kidney upper pole on DMSA renal scan	75	Inguinal hernia	Survived (5)
2	1	> 3 (4)		75	Cephalhematoma	Survived (5)
3	1	> 3 (102)	Hydroureter	128	Epidural hematoma	Died (133)
					Pectus excavatum
					Wormian bones
					Cephalhematoma
4	3	2 (35)	None	136	Inguinal hernia	Died (121)
4	3	2 (35)	None	136	Hip dislocation	Died (121)
5	1	> 3 (12)	None	83	Pectus excavatum	Lost to F-U (38)
5	1	> 3 (12)	None	83	Inguinal hernia	Lost to F-U (38)
6	1	3 (54)	Neurogenic bladder^a	74	Pectus excavatum	Survived (83)
					Failure to thrive
					Hip dislocation
7	> 3	1 (27)	Vesicoureteral reflux^b	Unknown	Pectus excavatum	Survived (74)
7	> 3	1 (27)	Neurogenic bladder	Unknown	Pectus excavatum	Survived (74)
8	1	> 3 (17)	None	Unknown	Subdural hematoma	Lost to F-U (22)
9	1	0	None	116	Pectus excavatum	Lost to F-U (29)
					Inguinal hernia
					Failure to thrive
10	0	0	None	129	None	Lost to F-U (9)
11	0	0	None	72	None	Lost to F-U (8)
12	0	Not evaluated	Not evaluated	111	Cephalhematoma	Lost to F-U (10)
13	0	Not evaluated	Not evaluated	Unknown	Diaphragmatic hernia	Survived (6)
14	0	Not evaluated	Not evaluated	146	None	Survived (84)

Pt = patients, UTI = urinary tract infection, DMSA = technetium-99m dimercaptosuccinic acid renal scan, F-U = follow-up.

^aBladder diverticulectomy was done; ^bUreteroneocystostomy was done; ^cEstimated glomerular filtration rate calculated by the revised Schwartz equation (mL/min/1.73 m²).

Disease course and prognosis

All patients had neurodevelopmental delay of various severity levels, and 11 patients took long-term antiepileptic drugs because of intractable seizures. Two patients (patients 8 and 14) were treated with periodic subcutaneous injections of copper-histidine, but the treatment did not affect the overall disease course. Five patients underwent tracheostomy and percutaneous endoscopic gastrostomy, and one other patient needed a nasal biphasic positive airway pressure support.

Two patients died at the ages of 10 and 11 years, respectively, at the end of palliative care at home, and six patients were lost to follow-up at a median age of 16 months (ranges, 8–38 months). The median current age of four surviving patients was 75 months (ranges, 5–83 months). The median estimated glomerular filtration rate (calculated by the revised Schwartz equation, n = 11) at the last follow-up was 118 mL/min/1.73 m² (ranges, 72–327). Four patients had stage II chronic kidney disease (Table 2).

DISCUSSION

MD is a lethal multisystemic disorder of copper metabolism, presenting with progressive neurodegeneration and connective tissue disturbances, together with characteristic “kinky” hair, as the main manifestations.1 2 3 MD is inherited as an X-linked recessive trait and therefore the vast majority of patients are men. There was one girl patient (patient 14) in our study, who showed normal initial serum copper and ceruloplasmin levels and had milder symptoms and older age onset than the boy patients. The clinical symptoms of MD in girl are caused by skewed inactivation of the X chromosome that harbors the mutation15 or translocation between the X chromosome and an autosome.16 Patient 14 in our study had a missense mutation in ATP7A, without evidence of chromosomal translocation.

Patients usually present with early-onset neurodevelopmental delay and uncontrolled intractable seizures. The neurological deficits are all irreversible, and most of the severely affected patients died before the third year of life.3 Patients in this study also showed similar poor prognosis.

MD is caused by mutations in the ATP7A gene.17 18 19 20 21 To date, 354 disease-causing or potentially disease-causing mutations in ATP7A have been reported (HGMD^® Professional 2018.2, https://portal.biobase-international.com/hgmd/pro/start.php) in association with MD or its variant phenotypes: missense/nonsense mutations, 114 (32%); splicing substitutions, 69 (19%); gross deletions, 65 (18%); small deletions, 58 (16%); and others. The mutations are distributed almost equally throughout the gene, without any hot spot. In our study, large deletions were the most common of the mutations.

Urologic complications are frequent in MD, with bladder diverticula being the most common one.13 The ATP7A protein is an energy-dependent, transmembrane protein that is involved in the delivery of copper to the secreted copper enzymes and in the export of surplus copper from the cells. Defective cellular copper transport in MD leads to altered activity of various kinds of cuproenzymes and the consequent diverse phenotypes of MD.12 Lysyl oxidase, a copper-dependent and elastic-fiber-associated cuproenzyme, is known to be responsible for lysine-derived cross-linking of collagen and elastin in connective tissue. Defective function of lysyl oxidase in MD results in an altered elastic-fiber morphology, which leads to arterial tortuosities, bladder diverticula and other elastic tissue pathologies, including premature rupture of fetal membranes, cephalohematoma, subdural hematoma, abnormal facies, high-arched palate, emphysema, hernias, loose skin and joints, osteoporosis, petechial hemorrhage, poor wound healing, and central nervous system degeneration.12 22 23 In 2006, Zaffanello et al.13 performed a retrospective review of 57 cases of MD, including 55 published case reports and two of their own cases, focusing on urological complications. They reported that the prevalence of bladder diverticulum was 38.6% of the total number of patients. However, most of the reports that they reviewed did not focus specifically on urological complication and therefore the prevalence of urological complications may have been underestimated. In addition, urological imaging studies are usually performed only in patients with urological problems, including urinary tract infections, voiding problems, etc. Therefore, urological complications are more likely to be found in older patients with longer follow-up periods. In fact, Zaffanello et al.13 reported that the number of urological complications increased progressively with the age of the patients. The prevalence of urological complications in our study was high: 8 (57.1%) of a total of 14 patients or 8 (72.7%) of 11 patients in whom urological evaluation was performed, which may be closer to the actual prevalence. A longitudinal cohort study, rather than a cross-sectional study, is needed to clarify this issue.

The diverticula in MD are usually multiple and vary in size and location, as shown in our study. Although the pathogenesis of bladder diverticula in MD has not been fully elucidated yet, it may result from impaired elasticity of the bladder muscle layer, caused by lysyl oxidase dysfunction,12 as well as disturbed innervation of the bladder in association with severe progressive neurodegenerative changes.24 In our study, two patients had neurogenic bladder dysfunction. Since lysyl oxidase activity cannot be corrected by parenteral copper administration, connective tissue laxity and the progression of urological complications cannot be completely improved.25 However, Zaffanello et al.13 showed that the progression of urological complications may be delayed with copper treatment. In our study, only two patients (patients 8 and 14) were treated with parenteral copper: patient 8 demonstrated bladder diverticula on imaging studies performed at the age of 17 months after an episode of urinary tract infection, and patient 14, a girl patient with a mild phenotype, did not undergo urological imaging studies because of the absence of urinary tract infection.

Bladder diverticula result in urinary stasis with a high residual urine volume, which leads to infections and further bladder dysfunction. Therefore, the main goal of management in patients with bladder diverticula is to accomplish complete bladder emptying with clean intermittent catheterization or open surgical drainage in severe cases.26 27 28 Two of our patients underwent urological intervention. However, because of its rarity, no consensus on the treatment of bladder diverticula in patients with MD is available. Furthermore, whether surgical treatment is warranted given the propensity of bladder diverticula to recur and the generally short expected life span of these patients remains to be elucidated.29 Therefore, surgical intervention should be considered based on the clinical condition of each patient, including the severity of urological problems, expected life expectancy, and tolerance to general anaesthesia.29 30

In conclusion, urological complications are very frequent in MD, with bladder diverticula being the most common. Bladder diverticula predispose patients with MD to urinary stasis, recurrent urinary tract infections, and renal parenchymal damage. Therefore, urological imaging studies and appropriate management of urological complications are required in all patients with MD.

Notes

^Funding This study was supported by a grant of the Korea Health Technology Research and Development Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea (HI18C0013).

^Disclosure The authors have no potential conflicts of interest to disclose.

^{Author Contributions}

Conceptualization: Cheong HI.
Data curation: Kim MY, Kim JH, Cho MH, Kim SH.
Formal analysis: Kim MY, Kim JH, Cho MH.
Investigation: Kim MY, Choi YH, Park K, Chae JH.
Methodology: Im YJ, Kang HG.
Validation: Choi YH, Im YJ, Kang HG, Chae JH, Cheong HI.
Writing - original draft: Kim MY.
Writing - review & editing: Choi YH, Kim SH, Park K, Kang HG, Chae JH, Cheong HI.

References

1. Menkes JH, Alter M, Steigleder GK, Weakley DR, Sung JH. A sex-linked recessive disorder with retardation of growth, peculiar hair, and focal cerebral and cerebellar degeneration. Pediatrics. 1962; 29(5):764–779.

2. Danks DM, Campbell PE, Walker-Smith J, Stevens BJ, Gillespie JM, Blomfield J, et al. Menkes' kinky-hair syndrome. Lancet. 1972; 1(7760):1100–1102.

3. Tümer Z, Møller LB. Menkes disease. Eur J Hum Genet. 2010; 18(5):511–518.

4. Vulpe C, Levinson B, Whitney S, Packman S, Gitschier J. Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase. Nat Genet. 1993; 3(1):7–13.

5. Chelly J, Tümer Z, Tønnesen T, Petterson A, Ishikawa-Brush Y, Tommerup N, et al. Isolation of a candidate gene for Menkes disease that encodes a potential heavy metal binding protein. Nat Genet. 1993; 3(1):14–19.

6. Mercer JF, Livingston J, Hall B, Paynter JA, Begy C, Chandrasekharappa S, et al. Isolation of a partial candidate gene for Menkes disease by positional cloning. Nat Genet. 1993; 3(1):20–25.

7. El Meskini R, Culotta VC, Mains RE, Eipper BA. Supplying copper to the cuproenzyme peptidylglycine alpha-amidating monooxygenase. J Biol Chem. 2003; 278(14):12278–12284.

8. Kodama H, Okabe I, Yanagisawa M, Kodama Y. Copper deficiency in the mitochondria of cultured skin fibroblasts from patients with Menkes syndrome. J Inherit Metab Dis. 1989; 12(4):386–389.

9. Petris MJ, Strausak D, Mercer JF. The Menkes copper transporter is required for the activation of tyrosinase. Hum Mol Genet. 2000; 9(19):2845–2851.

10. Qin Z, Itoh S, Jeney V, Ushio-Fukai M, Fukai T. Essential role for the Menkes ATPase in activation of extracellular superoxide dismutase: implication for vascular oxidative stress. FASEB J. 2006; 20(2):334–336.

11. Royce PM, Camakaris J, Danks DM. Reduced lysyl oxidase activity in skin fibroblasts from patients with Menkes' syndrome. Biochem J. 1980; 192(2):579–586.

12. Horn N, Tümer Z. Menkes disease and the occipital horn syndrome. In : Royce PM, Steinmann B, editors. Connective Tissue and Its Heritable Disorders: Molecular, Genetic, and Medical Aspects. 2nd ed. New York, NY: John Wiley and Sons Inc.;2002. p. 651–685.

13. Zaffanello M, Maffeis C, Fanos V, Franchini M, Zamboni G. Urological complications and copper replacement therapy in childhood Menkes syndrome. Acta Paediatr. 2006; 95(7):785–790.

14. Lee JS, Lim BC, Kim KJ, Hwang YS, Cheon JE, Kim IO, et al. Menkes disease in Korea: ATP7A mutation and epilepsy phenotype. Brain Dev. 2015; 37(2):223–229.

15. Smpokou P, Samanta M, Berry GT, Hecht L, Engle EC, Lichter-Konecki U. Menkes disease in affected females: the clinical disease spectrum. Am J Med Genet A. 2015; 167A(2):417–420.

16. Møller LB, Lenartowicz M, Zabot MT, Josiane A, Burglen L, Bennett C, et al. Clinical expression of Menkes disease in females with normal karyotype. Orphanet J Rare Dis. 2012; 7(1):6.

17. Das S, Levinson B, Whitney S, Vulpe C, Packman S, Gitschier J. Diverse mutations in patients with Menkes disease often lead to exon skipping. Am J Hum Genet. 1994; 55(5):883–889.

18. Tümer Z, Møller LB, Horn N. Mutation spectrum of ATP7A, the gene defective in Menkes disease. Adv Exp Med Biol. 1999; 448:83–95.

19. Gu YH, Kodama H, Murata Y, Mochizuki D, Yanagawa Y, Ushijima H, et al. ATP7A gene mutations in 16 patients with Menkes disease and a patient with occipital horn syndrome. Am J Med Genet. 2001; 99(3):217–222.

20. Tümer Z, Birk Møller L, Horn N. Screening of 383 unrelated patients affected with Menkes disease and finding of 57 gross deletions in ATP7A. Hum Mutat. 2003; 22(6):457–464.

21. Møller LB, Bukrinsky JT, Mølgaard A, Paulsen M, Lund C, Tümer Z, et al. Identification and analysis of 21 novel disease-causing amino acid substitutions in the conserved part of ATP7A . Hum Mutat. 2005; 26(2):84–93.

22. Rucker RB, Kosonen T, Clegg MS, Mitchell AE, Rucker BR, Uriu-Hare JY, et al. Copper, lysyl oxidase, and extracellular matrix protein cross-linking. Am J Clin Nutr. 1998; 67(5):Suppl. 996S–1002S.

23. Urbán Z, Boyd CD. Elastic-fiber pathologies: primary defects in assembly-and secondary disorders in transport and delivery. Am J Hum Genet. 2000; 67(1):4–7.

24. Harcke HT Jr, Capitanio MA, Grover WD, Valdes-Dapena M. Bladder diverticula and Menkes' syndrome. Radiology. 1977; 124(2):459–461.

25. Kodama H, Murata Y, Kobayashi M. Clinical manifestations and treatment of Menkes disease and its variants. Pediatr Int. 1999; 41(4):423–429.

26. Oshio T, Hino M, Kirino A, Matsumura C, Fukuda K. Urologic abnormalities in Menkes' kinky hair disease: report of three cases. J Pediatr Surg. 1997; 32(5):782–784.

27. Eradi B, Rajimwale A. Excision of massive bladder diverticula in Menkes disease. J Pediatr Urol. 2010; 6(3):312–314.

28. Kageyama S, Okada Y, Konishi T, Koizumi S, Tomoyoshi T. Menkes' kinky hair disease associated with a large bladder diverticulum: a case report. Int J Urol. 1997; 4(3):318–320.

29. Hebert KL, Martin AD. Management of bladder diverticula in Menkes syndrome: a case report and review of the literature. Urology. 2015; 86(1):162–164.

30. Tobias JD. Anaesthetic considerations in the child with Menkes' syndrome. Can J Anaesth. 1992; 39(7):712–715.

TOOLS

ORCID iDs

Mi Young Kim
https://orcid.org/0000-0002-2574-5282

Ji Hyun Kim
https://orcid.org/0000-0001-8477-0157

Myung Hyun Cho
https://orcid.org/0000-0002-3237-3173

Young Hun Choi
https://orcid.org/0000-0002-1842-9062

Seong Heon Kim
https://orcid.org/0000-0001-8003-3010

Young Jae Im
https://orcid.org/0000-0002-8285-483X

Kwanjin Park
https://orcid.org/0000-0002-8926-3047

Hee Gyung Kang
https://orcid.org/0000-0001-8323-5320

Jong-Hee Chae
https://orcid.org/0000-0002-9162-0138

Hae Il Cheong
https://orcid.org/0000-0001-7556-1265

Similar articles